Optimized adoptive T-cell therapy for the treatment of residual mantle cell lymphoma

Corey M. Munger, Ganapati V. Hegde, Dennis D. Weisenburger, Julie M. Vose, Shantaram S. Joshi

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Mantle cell lymphoma (MCL) is an aggressive B-cell neoplasm with few patients achieving long-term survival with current treatment regimens. High-dose therapy is effective in reducing the tumor burden; however, patients eventually relapse due to minimal residual disease. Having demonstrated efficacy in other malignancies, the effectiveness of dendritic cell-based immunotherapy for minimal residual MCL was examined. We demonstrated that dendritic cells (DC) primed with MCL antigens stimulated the activation of MCL-specific T cells that recognized and destroyed both MCL cell lines and primary MCL in vitro. In addition, in vivo studies demonstrated that adoptively transferred MCL-specific T cells were able to significantly inhibit tumor growth in mice with minimal residual MCL. Subsequently, when combined with CHOP chemotherapy, adoptive T-cell therapy was able to significantly extend the survival of the mice by further reducing the tumor burden. These results clearly show that MCLspecific cellular immunotherapy is effective in treating minimal residual MCL, paving the way for future clinical studies.

Original languageEnglish (US)
Pages (from-to)1819-1832
Number of pages14
JournalCancer Immunology, Immunotherapy
Volume61
Issue number10
DOIs
StatePublished - Oct 1 2012

    Fingerprint

Keywords

  • Adoptive T-cell transfer
  • Dendritic cells
  • Immunotherapy
  • Mantle cell lymphoma
  • Minimal residual tumor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this